Differential expression of lumican and fatty acid binding protein-1: New insights into the histologic spectrum of nonalcoholic fatty liver disease

Hepatology

Volumn 49, Issue 4, 2009, Pages 1375-1384

  Charlton, Michael ^a   Viker, Kimberly ^a   Krishnan, Anuradha ^a   Sanderson, Schuyler ^a   Veldt, Bart ^a   Kaalsbeek, A J ^a   Kendrick, Michael ^a   Thompson, Geoffrey ^a   Que, Florencia ^a   Swain, James ^a   Sarr, Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN FIBRIL; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 1; LUMICAN; SMOOTH MUSCLE ACTIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; FABP1 PROTEIN, HUMAN; KERATAN SULFATE; MESSENGER RNA; PROTEOCHONDROITIN SULFATE;

ARTICLE; BODY MASS; CANCER STAGING; CONTROLLED STUDY; DISEASE COURSE; FATTY ACID TRANSPORT; FATTY LIVER; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPID LIVER LEVEL; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TIME OF FLIGHT MASS SPECTROMETRY; ADULT; COMPARATIVE STUDY; FEMALE; ISOLATION AND PURIFICATION; LIVER; MALE; METABOLISM; MIDDLE AGED; OBESITY; PATHOLOGY; POLYMERASE CHAIN REACTION; PROTEOMICS; TANDEM MASS SPECTROMETRY;

ADULT; FATTY ACID-BINDING PROTEINS; FATTY LIVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATAN SULFATE; LIVER; MALE; MIDDLE AGED; OBESITY; POLYMERASE CHAIN REACTION; PROTEOCHONDROITIN SULFATES; PROTEOMICS; RNA, MESSENGER; TANDEM MASS SPECTROMETRY;

EID: 65449121797     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22927     Document Type: Article

References (42)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
2. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. HEPATOLOGY1990;12:1106-1110.
3. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979;67:811-816.
4. Diehl AM, Goodman Z, Ishak KG. Alcohol like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988;95:1056-1062.
5. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120: 1183-1192.
6. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. HEPATOLOGY2003;37:917-923. Erratum in: HEPATOLOGY 2003;38:536.
7. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005;129:113-121.
8. Charlton M. Nonalcoholic fatty liver disease: A review of current understanding and future impact. Clin Gastroenterol Hepatol 2004;2:1048-1058.
9. Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996;62:1802-1805.
10. Angulo P. Nonalcoholic fatty liver disease and liver transplantation. N Engl J Med 2006;12:523-534.
11. Frantzides CT, Carlson MA, Moore RE, Zografakis JG, Madan AK, Puumala S, et al. Effect of body mass index on nonalcoholic fatty liver disease in patients undergoing minimally invasive bariatric surgery. J Gastrointest Surg 2004;8:849-855.
12. Silvestre V, Ruano M, Garcia-Lescun MC, Aguirregoicoa E, Criado L, Rodriguez A, et al. Morbid obesity, non-alcoholic fatty liver disease, metabolic syndrome and bariatric surgery [in Spanish]. Nutr Hosp 2007;22: 602-606.
13. Solga SF, Clark JM, Alkhuraishi AR, Torbenson M, Tabesh A, Schweitzer M, et al. Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients. Surg Obes Relat Dis 2005;1:6-11.
14. Brezillon S, Venteo L, Ramont L, D'Onofrio MF, Perreau C, Pluot M, et al. Expression of lumican, a small leucine-rich proteoglycan with antitumour activity, in human malignant melanoma. Clin Exp Dermatol 2007; 32:405-416.
15. Dolhnikoff M, Morin J, Roughley PJ, Ludwig MS. Expression of lumican in human lungs. Am J Respir Cell Mol Biol 1998;19:582-587.
16. Saika S, Miyamoto T, Tanaka S, Tanaka T, Ishida I, Ohnishi Y, et al. Response of lens epithelial cells to injury: Role of lumican in epithelial-mesenchymal transition. Invest Ophthalmol Vis Sci 2003;44:2094-2102.
17. Saika S, Shiraishi A, Liu CY, Funderburgh JL, Kao CW, Converse RL, et al. Role of lumican in the corneal epithelium during wound healing. J Biol Chem 2000;275:2607-2612.
18. Blochberger TC, Vergnes JP, Hempel J, Hassell JR. cDNA to chick lumican (corneal keratan sulfate proteoglycan) reveals homology to the small interstitial proteoglycan gene family and expression in muscle and intestine. J Biol Chem 1992;267:347-352.
19. Chakravarti S. Functions of lumican and fibromodulin: Lessons from knockout mice. Glycoconj J 2002;19:287-293.
20. Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, LaMantia C, Carroll H. Lumican regulates collagen fibril assembly: Skin fragility and corneal opacity in the absence of lumican. J Cell Biol 1998;141:1277-1286.
21. Corpuz LM, Dunlevy JR, Hassell JR, Conrad AH, Conrad GW. Molecular cloning and relative tissue expression of decorin and lumican in embryonic quail cornea. Matrix Biol 2000;19:699-704.
22. Vij N, Roberts L, Joyce S, Chakravarti S. Lumican regulates corneal inflammatory responses by modulating Fas-Fas ligand signaling. Invest Ophthalmol Vis Sci 2005;46:88-95.
23. Vij N, Roberts L, Joyce S, Chakravarti S. Lumican suppresses cell proliferation and aids Fas-Fas ligand mediated apoptosis: Implications in the cornea. Exp Eye Res 2004;78:957-971.
24. Krull NB, Gressner AM. Differential expression of keratan sulphate proteoglycans fibromodulin, lumican and aggrecan in normal and fibrotic rat liver. FEBS Lett 1992;312:47-52.
25. Xie L, Tsaprailis G, Chen QM. Proteomic identification of insulin-like growth factor-binding protein-6 induced by sublethal H2O2 stress from human diploid fibroblasts. Mol Cell Proteomics 2005;4:1273-1283.
26. Winokur ST, Barrett K, Martin JH, Forrester JR, Simon M, Tawil R, et al. Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress. Neuromuscul Disord 2003;13: 322-333.
27. Wu F, Chakravarti S. Differential expression of inflammatory and fibrogenic genes and their regulation by NF-kappaB inhibition in a mouse model of chronic colitis. J Immunol 2007;179:6988-7000.
28. Funderburgh JL, Mitschler RR, Funderburgh ML, Roth MR, Chapes SK, Conrad GW. Macrophage receptors for lumican. A corneal keratan sulfate proteoglycan. Invest Ophthalmol Vis Sci 1997;38:1159-1167.
29. Wu F, Vij N, Roberts L, Lopez-Briones S, Joyce S, Chakravarti S. A novel role of the lumican core protein in bacterial lipopolysaccharide-induced innate immune response. J Biol Chem 2007;282:26409-26417.
30. MacArthur JM, Bishop JR, Stanford KI, Wang L, Bensadoun A, Witztum JL, et al. Liver heparan sulfate proteoglycans mediate clearance of triglyceride rich lipoproteins independently of LDL receptor family members. J Clin Invest 2007;117:153-164.
31. Cistola DP, Sacchettini JC, Banaszak LJ, Walsh MT, Gordon JI. Fatty acid interactions with rat intestinal and liver fatty acid-binding proteins expressed in Escherichia coli. A comparative 13C NMR study. J Biol Chem 1989;264:2700-2710.
32. Woodford JK, Behnke WD, Schroeder F. Liver fatty acid binding protein enhances sterol transfer by membrane interaction. Mol Cell Biochem 1995;152:51-62.
33. Cistola DP, Walsh MT, Corey RP, Hamilton JA, Brecher P. Interactions of oleic acid with liver fatty acid binding protein: A carbon-13 NMR study. Biochemistry 1988;27:711-717.
34. Newberry EP, Kennedy SM, Xie Y, Sternard BT, Luo J, Davidson NO. Diet-induced obesity and hepatic steatosis in L-FABP-/- mice is abrogated with SF, but not PUFA, feeding and attenuated after cholesterol supplementation. Am J Physiol Gastrointest Liver Physiol 2008;294:G307-G314.
35. Atshaves BP, McIntosh AM, Lyuksyutova OI, Zipfel W, Webb WW, Schroeder F. Liver fatty acid-binding protein gene ablation inhibits branched-chain fatty acid metabolism in cultured primary hepatocytes. J Biol Chem 2004;279:30954-30965.
36. Martin GG, Danneberg H, Kumar LS, Atshaves BP, Erol E, Bader M, et al. Decreased liver fatty acid binding capacity and altered liver lipid distribution in mice lacking the liver fatty acid-binding protein gene. J Biol Chem 2003;278:21429-21438.
37. Newberry EP, Xie Y, Kennedy S, Han X, Buhman KK, Luo J, et al. Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene. J Biol Chem 2003;278:51664-51672.
38. Veerkamp JH, van Moerkerk HT. Fatty acid-binding protein and its relation to fatty acid oxidation. Mol Cell Biochem 1993;123:101-106.
39. Kaikaus RM, Sui Z, Lysenko N, Wu NY, Ortiz de Montellano PR, Ockner RK, et al. Regulation of pathways of extramitochondrial fatty acid oxidation and liver fatty acid-binding protein by long-chain monocarboxylic fatty acids in hepatocytes. Effect of inhibition of carnitine palmitoyltransferase I. J Biol Chem 1993;268:26866-26871.
40. Newberry EP, Xie Y, Kennedy SM, Luo J, Davidson NO. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. HEPATOLOGY2006;44:1191-1205.
41. Charlton M, Angulo P, Chalasani N, Merriman R, Viker K, Charatcharoenwitthaya P, et al. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. HEPATOLOGY2008;47:484-492.
42. Ashida K, Goto K, Zhao Y, Okabe T, Yanase T, Takayanagi R, et al. Dehydroepiandrosterone negatively regulates the p38 mitogen-activated protein kinase pathway by a novel mitogen-activated protein kinase phosphatase. Biochim Biophys Acta 2005;1728:84-94.